GlassScriptPhysician profile
Michelle M Meyers
NPI 1205244860
$1,096.70
in general payments reported to CMS, 2019-2025
19 companies · $570 in 2025
The $570 reported for 2025 was more than what 85% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
See the full distribution for Critical Care Medicine (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $132 · 2023: $191 · 2024: $204 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $281.55 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Viatris Specialty LLC | $114.05 | 2025 | Yupelri |
| Baxter Healthcare | $101.62 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $77.27 | 2022-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $65.88 | 2022-2025 | Dupixent |
| Grifols USA, LLC | $64.48 | 2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.94 | 2023-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $52.96 | 2022-2025 | Opsumit, Uptravi |
| Axsome Therapeutics, INC. | $43.87 | 2024-2025 | Sunosi |
| Genzyme Corporation | $43.17 | 2023 | |
| Amgen INC. | $39.11 | 2024-2025 | Tezspire |
| Csl Behring | $26.41 | 2023 | Hizentra |
| Inspire Medical Systems, INC. | $24.40 | 2025 | Inspire |
| Mylan Specialty L.P. | $23.01 | 2024 | Yupelri |
| Tactile Systems Technology INC | $17.39 | 2023 | Flexitouch Plus, Entre Plus |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $17.35 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $17.12 | 2025 | Tyvaso |
| Insmed, INC. | $13.85 | 2025 | Arikayce |
| Teva Pharmaceuticals USA, INC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Meyers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.